Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Feb 28, 2022
- Accession no.
- 0000899243-22-008145
- Filed
- Feb 28, 2022, 5:53 PM ET
- Trade date
- Feb 24-25, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $111.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | Director, 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | Director, 10% Owner |
| Boyd StevenCIK 0001706140 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2022 | Common Stock | PPurchaseAcquired | +100,000 | $0.8009 | +$80,090 | 46,800,000 | Indirect | |
| Feb 25, 2022 | Common Stock | PPurchaseAcquired | +40,000 | $0.7929 | +$31,716 | 46,840,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.